The “sleeper” biotech highlighted in today’s article, a company with a unique name and focused on therapies for very rare, pediatric cancers, has a promising pipeline – including two drugs that could be approved in the next year. This, combined with the fact that its stock price has steadily increased since its IPO (despite getting caught up in the coronavirus market sell-off), leads the author to recommend investors keep this company on their radars for potential buy the dip opportunities. For the biotech stock in question, CLICK HERE.
Why This Cancer-Fighting Biotech With A Unique Name And Focus Belongs On Your Radar
Tags:Biotech InvestmentsBiotech StocksCoronavirus Market Sell-OffInvestPotential BuysSleeper BiotechStock MarketStock Pricestocks